- Home
- SMSI vs NXTC Comparison
SMSI vs NXTC Comparison
Compare SMSI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- NXTC
- Stock Information
- Founded
- SMSI 1982
- NXTC 2015
- Country
- SMSI United States
- NXTC United States
- Employees
- SMSI N/A
- NXTC N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- SMSI Technology
- NXTC Health Care
- Exchange
- SMSI Nasdaq
- NXTC Nasdaq
- Market Cap
- SMSI 16.7M
- NXTC 13.9M
- IPO Year
- SMSI 1995
- NXTC 2019
- Fundamental
- Price
- SMSI $0.89
- NXTC $5.01
- Analyst Decision
- SMSI Strong Buy
- NXTC Strong Buy
- Analyst Count
- SMSI 1
- NXTC 3
- Target Price
- SMSI $5.00
- NXTC $33.00
- AVG Volume (30 Days)
- SMSI 293.0K
- NXTC 20.2K
- Earning Date
- SMSI 07-31-2025
- NXTC 07-31-2025
- Dividend Yield
- SMSI N/A
- NXTC N/A
- EPS Growth
- SMSI N/A
- NXTC N/A
- EPS
- SMSI N/A
- NXTC N/A
- Revenue
- SMSI $19,378,000.00
- NXTC N/A
- Revenue This Year
- SMSI $10.12
- NXTC N/A
- Revenue Next Year
- SMSI $63.12
- NXTC N/A
- P/E Ratio
- SMSI N/A
- NXTC N/A
- Revenue Growth
- SMSI N/A
- NXTC N/A
- 52 Week Low
- SMSI $0.52
- NXTC $2.69
- 52 Week High
- SMSI $2.57
- NXTC $21.48
- Technical
- Relative Strength Index (RSI)
- SMSI 47.81
- NXTC 47.80
- Support Level
- SMSI $0.87
- NXTC $4.60
- Resistance Level
- SMSI $1.30
- NXTC $5.37
- Average True Range (ATR)
- SMSI 0.10
- NXTC 0.50
- MACD
- SMSI 0.00
- NXTC -0.01
- Stochastic Oscillator
- SMSI 20.94
- NXTC 47.86
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.